A downtrend has been apparent in AlloVir, Inc. (ALVR) lately with too much selling pressure. The stock has declined 72.4% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________to __________________ Commission File Number: 001-39409 ALLOVIR, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________to __________________ Commission File Number: 001-39409 ALLOVIR, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State ...

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements (unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) This section presents the unaudited condensed consolidated financial statements for Q1 2023, detailing a **net loss of $41.2 million** and **total assets of $244.0 million** [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Condensed Consolidated Balance Sheet Highlights (Unaudited) | Balance Sheet Items | March 31, 2023 (in thousands USD) | December 31, 2022 (in thousands USD) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $115,698 | $106,092 | | Short-term investments | $86,872 | $127,703 | | Total current assets | $212,275 | $243,052 | | **Total assets** | **$244,044** | **$277,079** | | **Liabilities & Stockholders' Equity** | | | | Total current liabilities | $24,959 | $24,338 | | Total liabilities | $50,512 | $52,560 | | Total stockholders' equity | $193,532 | $224,519 | | **Total liabilities and stockholders' equity** | **$244,044** | **$277,079** | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Statement of Operations Summary (Unaudited) | Metric | Three Months Ended March 31, 2023 (in thousands USD) | Three Months Ended March 31, 2022 (in thousands USD) | | :--- | :--- | :--- | | Research and development | $30,718 | $29,067 | | General and administrative | $12,513 | $14,126 | | **Loss from operations** | **$(43,231)** | **$(43,193)** | | Interest income | $1,325 | $148 | | **Net loss** | **$(41,183)** | **$(43,863)** | | **Net loss per share — basic and diluted** | **$(0.44)** | **$(0.69)** | [Condensed Consolidated Statements of Changes in Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders'%20Equity) - Total stockholders' equity decreased from **$224.5 million** at December 31, 2022, to **$193.5 million** at March 31, 2023, primarily driven by the **net loss of $41.2 million**, partially offset by **$10.0 million** in stock-based compensation[33](index=33&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash Flow Summary (Unaudited) | Cash Flow Activity | Three Months Ended March 31, 2023 (in thousands USD) | Three Months Ended March 31, 2022 (in thousands USD) | | :--- | :--- | :--- | | Net cash used in operating activities | $(32,118) | $(46,476) | | Net cash provided by (used in) investing activities | $41,724 | $(54,979) | | Net increase (decrease) in cash, cash equivalents, and restricted cash | $9,606 | $(101,455) | | Cash, cash equivalents, and restricted cash at end of period | $116,550 | $101,058 | [Notes to Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) - AlloVir is a late clinical-stage cell therapy company, with its lead product, posoleucel, in three ongoing Phase 3 trials expected to report data in 2024, following positive Phase 2 results in February 2023[38](index=38&type=chunk) - The company believes its **$202.6 million** in cash, cash equivalents, and short-term investments as of March 31, 2023, are sufficient to fund planned operations for at least twelve months, addressing going concern considerations[40](index=40&type=chunk)[44](index=44&type=chunk) - The adoption of ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326), on January 1, 2023, did not materially impact the condensed consolidated financial statements[52](index=52&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=16&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial condition and operational results, reporting a **net loss of $41.2 million** for Q1 2023, with **$202.6 million** in cash sufficient for twelve months of operations - The company's lead product, posoleucel, is in three ongoing Phase 3 registrational trials with data readouts expected in 2024, following positive Phase 2 results for BK viremia in kidney transplant patients in February 2023[89](index=89&type=chunk) Comparison of Operating Expenses (in thousands USD) | Expense Category | Three Months Ended March 31, 2023 (in thousands USD) | Three Months Ended March 31, 2022 (in thousands USD) | Change (in thousands USD) | | :--- | :--- | :--- | :--- | | Research and development | $30,718 | $29,067 | $1,651 | | General and administrative | $12,513 | $14,126 | $(1,613) | | **Total operating expenses** | **$43,231** | **$43,193** | **$38** | - As of March 31, 2023, the company held **$202.6 million** in cash, cash equivalents, and short-term investments, which management believes is sufficient to fund operations and capital expenditures for at least the next twelve months[94](index=94&type=chunk)[115](index=115&type=chunk) - Net cash used in operating activities decreased to **$32.1 million** in Q1 2023 from **$46.5 million** in Q1 2022, primarily due to the timing of changes in net operating assets and liabilities[123](index=123&type=chunk)[124](index=124&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=23&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, the company is not required to provide disclosures for this item - As a smaller reporting company, AlloVir is not required to disclose quantitative and qualitative information about market risk[134](index=134&type=chunk) [Item 4. Controls and Procedures](index=23&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2023, with no material changes to internal control over financial reporting - The company's management, including the CEO and CFO, concluded that disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2023[136](index=136&type=chunk) - No material changes in the company's internal control over financial reporting occurred during the quarter[137](index=137&type=chunk) [PART II. OTHER INFORMATION](index=25&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=25&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently a party to any material legal proceedings - As of the reporting date, the company is not a party to any material arbitration or legal proceedings[141](index=141&type=chunk) [Item 1A. Risk Factors](index=25&type=section&id=Item%201A.%20Risk%20Factors) This section outlines key risks, including dependence on posoleucel's success, high development costs, need for additional funding, and intense competition - The company's business is highly dependent on its lead product candidate, posoleucel, and its ability to complete clinical testing and obtain regulatory approval[7](index=7&type=chunk)[179](index=179&type=chunk) - As a late clinical-stage entity, the company has incurred **net losses since inception**, with an **accumulated deficit of $507.0 million** as of March 31, 2023, and anticipates significant future losses[7](index=7&type=chunk)[216](index=216&type=chunk) - Substantial additional funding is required, and an inability to raise capital could force delays, reductions, or elimination of development programs or commercialization efforts[8](index=8&type=chunk)[220](index=220&type=chunk) - The company faces substantial competition from other pharmaceutical and biotechnology companies, which could significantly impact its commercial opportunities if competitors develop more successful products[10](index=10&type=chunk)[163](index=163&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=66&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no unregistered sales of equity securities during the period - There were no unregistered sales of equity securities during the quarter[280](index=280&type=chunk) [Item 3. Defaults Upon Senior Securities](index=66&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon senior securities - There were no defaults upon senior securities[280](index=280&type=chunk) [Item 4. Mine Safety Disclosures](index=66&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - This item is not applicable[280](index=280&type=chunk) [Item 5. Other Information](index=66&type=section&id=Item%205.%20Other%20Information) The company reports no other information for this period - There is no other information to report[280](index=280&type=chunk) [Item 6. Exhibits](index=67&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with Form 10-Q, including Sarbanes-Oxley certifications and Inline XBRL data files - Exhibits include certifications from the Principal Executive Officer and Principal Financial Officer pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act of 2002[285](index=285&type=chunk) - The report incorporates various Inline XBRL documents (Instance, Schema, Calculation, Definition, Label, Presentation) for financial data tagging[281](index=281&type=chunk)[282](index=282&type=chunk)[283](index=283&type=chunk)

Allogeneic, Off-the-Shelf, Virus-Specific T Cell Therapies in Late-Stage Development February 2023 ...

Product Development - The company is developing three innovative allogeneic virus-specific T cell (VST) therapy candidates targeting 11 different viruses, with the lead product posoleucel aimed at significantly improving outcomes for transplant patients [500]. - Posoleucel is currently being studied in three ongoing Phase 3 trials, with expected completion of enrollment by the end of 2023 and potential data readouts in 2024 [501]. - ALVR106 and ALVR107 are additional investigational VST therapies in development, targeting respiratory diseases and hepatitis B, respectively [502]. - The company has faced disruptions in clinical trials and operations due to the ongoing COVID-19 pandemic, impacting timelines and patient enrollment [511]. - The company expects to incur significant expenses and operating losses as it advances product candidates through clinical development and seeks regulatory approval [537]. Financial Performance - The company reported net losses of $168.7 million and $172.0 million for the years ended December 31, 2022 and 2021, respectively, with an accumulated deficit of $465.8 million as of December 31, 2022 [506]. - The net loss for the year ended December 31, 2022, was $168.7 million, an improvement from a net loss of $171.9 million in 2021 [527]. - Cash, cash equivalents, and short-term investments totaled $233.8 million as of December 31, 2022, expected to fund operations for at least twelve months [509]. - Net cash used in operating activities was $142.1 million for the year ended December 31, 2022, compared to $106.3 million in 2021 [543]. - Net cash provided by financing activities was $127.0 million for the year ended December 31, 2022, primarily from the issuance of common stock [546]. Expenses - The company has incurred significant operating losses primarily due to research and development activities and general administrative costs, with expectations of continued increasing expenses [507]. - Research and development expenses were $118.9 million for the year ended December 31, 2022, a decrease of $1.9 million from $120.7 million in 2021 [530]. - General and administrative expenses increased to $52.3 million in 2022 from $49.1 million in 2021, reflecting a $3.2 million increase [531]. Capital and Financing - The company has not generated any revenue from product sales and relies on capital raising through equity and debt financings to support operations [503]. - The company has received net cash proceeds of approximately $156.3 million from preferred stock sales and $292.0 million from common stock in its IPO [534]. - The relationship with ElevateBio includes shared management and support for drug development and manufacturing services, enhancing the company's operational capabilities [513]. Accounting and Compliance - The company utilizes U.S. GAAP for its consolidated financial statements, requiring estimates and judgments that may affect reported amounts of assets and liabilities [552]. - Stock-based compensation expense is recognized based on the grant date fair value, with a graded-vesting basis for performance conditions [554]. - The fair value of stock options is estimated using the Black-Scholes option-pricing model, considering factors such as expected volatility and risk-free interest rates [556]. - The company is classified as an "emerging growth company" under the JOBS Act, allowing it to delay compliance with certain accounting standards [562]. - The company will remain an emerging growth company until it meets specific revenue or market value thresholds, including total annual gross revenues of at least $1.0 billion [566]. - The company is also classified as a "smaller reporting company," with market value held by non-affiliates less than $700 million and annual revenue below $100 million [567]. - Recent accounting pronouncements that may impact financial position and results of operations are disclosed in the consolidated financial statements [568]. - As a smaller reporting company, the company is not required to disclose quantitative and qualitative disclosures about market risk [570].

Allogeneic, Off-the-Shelf, Virus-Specific T Cell Therapies in Late-Stage Development January 2023 ...